On Aug. 20, 2020, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which advanced into Phase 2/3 evaluation.

The manuscript described key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate that demonstrated strong immunogenicity in younger and older adults.